国产吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床观察  

The Clinical Observation of Fomestic Gemcabtine(ZEFEI) Combined with Cisplatin in the Treatment of Advanced NSCLC

作　　者：陈宝玉 房振羽 张鸣竹 

机构地区：[1]江苏省兴化市肿瘤医院肿瘤科,兴化225700

出　　处：《航空航天医学杂志》2013年第5期533-534,共2页Journal of Aerospace medicine

摘　　要：目的:吉西他滨已成为临床上治疗晚期非小细胞肺癌的主要药物之一,本研究观察国产盐酸吉西他滨(泽菲)联合顺铂治疗晚期非小细胞肺癌的近期临床疗效及毒性反应。方法:2008-01～2009-02治疗的晚期非小细胞肺癌35例。应用泽菲1.0 g/m2,静脉滴注d1、d8,顺铂30 mg/m2,静脉滴注d2～d4,21 d为1周期,连用2个周期评价疗效,至少行2个周期化疗。结果:35例患者中,近期临床疗效有效率42.8%,1年生存率为34.2%。主要毒副作用为血液学毒性。结论:泽菲联合顺铂治疗非小细胞肺癌,有较好的疗效,与进口健择相比,疗效相似。Objeclive：Gemcitabine is one of the major drugs for advanced non small cell lung canner（ NSCLC）treat ment in clinical use. To evaluate the effiaeacy and toxiciety reactions of domestic gemeitabine（ZEFEI） plus eisplatin in the treatment of advanced non small cell lung canner（NSCLC）. Methods ：35 patients with advanced NSCLC were trea ted with the combination of domestic gemcitabine（ZEFEI） and eisplatin, （ Gem 1.0 g/m2, ivgtt, dl dS, DDP, 30 mg/m2, ivgtt, d2 d4）. Each patient should complete no less than two cycle＇s chemotherapy. The patients were repeatedly treated every 3 weeks and evaluated the efficacy after cycles. Results：The respone rate was 42. 8% （ 15/35 ）. The 1 year survival rates were 34. 2%. The major toxieities were hematolog toxicites. Conclnsions：The domestic gemeitabine （ZEFEI） plus cisplatin combination is a highly effective regimen for treating advanced NSCLC, and it is worthy of farther clinical trial.

关 键 词：非小细胞肺癌 泽菲 顺铂 化疗 

分 类 号：R734.2[医药卫生—肿瘤]